檢索結果 - Mingshan Cheng

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    A rapid, sensitive, and reproducible in vivo PBMC humanized murine model for determining therapeutic‐related cytokine release syndrome

    A rapid, sensitive, and reproducible in vivo PBMC humanized murine model for determining therapeutic‐related cytokine release syndrome 由 Chunting Ye, Hongyuan Yang, Mingshan Cheng, Leonard D. Shultz, Dale L. Greiner, Michael A. Brehm, James Keck

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Enhanced Charge Collection in MOF‐525–PEDOT Nanotube Composites Enable Highly Sensitive Biosensing

    Enhanced Charge Collection in MOF‐525–PEDOT Nanotube Composites Enable Highly Sensitive Biosensing 由 Tzu‐Yen Huang, Chung‐Wei Kung, Yu‐Te Liao, Sheng−Yuan Kao, Mingshan Cheng, Ting‐Hsiang Chang, Joel Henzie, Hatem R. Alamri, Zeid A. ALOthman, Yusuke Yamauchi, Kuo‐Chuan Ho, Kevin C.‐W. Wu

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Humanized mice in studying efficacy and mechanisms of PD‐1‐targeted cancer immunotherapy

    Humanized mice in studying efficacy and mechanisms of PD‐1‐targeted cancer immunotherapy 由 Minan Wang, Li‐Chin Yao, Mingshan Cheng, Danying Cai, Jan Martínek, Chong-xian Pan, Wei Shi, Ai‐Hong Ma, Ralph W. Vere White, Susan Airhart, Edison T. Liu, Jacques Banchereau, Michael A. Brehm, Dale L. Greiner, Leonard D. Shultz, Karolina Palucka, James Keck

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Modeling of Patient-Derived Xenografts in Colorectal Cancer

    Modeling of Patient-Derived Xenografts in Colorectal Cancer 由 Αναστασία Κατσιαμπούρα, Kanwal Raghav, Zhi-Qin Jiang, David G. Menter, Andreas Varkaris, Maria Pia Morelli, Shanequa Manuel, Ji Yuan Wu, Alexey V. Sorokin, Bahar Salimian Rizi, Christopher A. Bristow, Feng Tian, Susan Airhart, Mingshan Cheng, Bradley M. Broom, Jeffrey S. Morris, Michael J. Overman, Garth Powis, Scott Kopetz

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

    Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions 由 Nicolas Floc’h, Matthew J. Martin, Jonathan W. Riess, Jonathan P. Orme, Anna D. Staniszewska, Ludovic Ménard, Maria Emanuela Cuomo, Daniel O’Neill, Richard A. Ward, M. Raymond V. Finlay, Darren McKerrecher, Mingshan Cheng, Daniel P. Vang, Rebekah A. Burich, James Keck, David R. Gandara, Philip C. Mack, Darren A.E. Cross

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: